Checkpoint Therapeutics, Inc. has announced an update on its planned merger with Sun Pharmaceutical Industries, Inc. The two companies have entered into an amended Agreement and Plan of Merger as of April 14, 2025. According to the terms of the merger, Checkpoint will merge with Snoopy Merger Sub, Inc., a wholly owned subsidiary of Sun Pharma, with Checkpoint continuing as the surviving entity and becoming a wholly owned subsidiary of Sun Pharma. The merger is expected to close on or about May 30, 2025, pending the required stockholder vote and other closing conditions. A special meeting for Checkpoint stockholders to vote on the merger is scheduled for May 28, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.